Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial
Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.
·1 source